Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study

Recent studies suggest that inhaled corticosteroids can adversely affect bone metabolism. The objective of this study was to evaluate the importance of these adverse effects in a case-control study. Bone mineral density (BMD) was measured in 48 asthmatic adults (15 males and 33 females) treated with inhaled steroids (beclomethasone or budesonide) and in 48 gender and age-matched healthy subjects at baseline and at 2 yrs. Vertebral BMD was measured by dual energy X-ray densitometry. Patients had been treated with a dose of 662 +/- 278 micrograms (range 300-1,000 micrograms) of beclomethasone dipropionate or budesonide for more than 1 yr (mean duration of treatment 10.6 yrs, range 1-16 yrs). Twenty four patients had needed 1-6 short courses of oral steroids and seven had received oral corticosteroids (mean daily dose 6.2 mg prednisone) for 2-15 yrs more than 4 yrs prior to the BMD measurements. During the follow-up, 14 patients required 1-3 short courses of oral steroids. There was no correlation either between inhaled corticosteroid doses or duration of treatment and BMD values. There were no significant differences in BMD baseline values between patients and healthy controls. BMD significantly decreased in both groups at 2 yrs, from 1.08 +/- 0.19 to 1.05 +/- 0.19 g.cm-2 (p = 0.002) in asthmatics versus 1.12 +/- 0.17 to 1.09 +/- 0.18 g.cm-2 (p = 0.008) in controls. There were no significant differences in BMD loss between patients and healthy controls. Furthermore, no differences were found in bone loss when pre- and postmenopausal women were compared with their healthy control counterparts. No differences in baseline BMD were found between patients who had received regular oral corticosteroid therapy or booster courses of oral corticosteroids and those who had not. Inhaled corticosteroid treatment at a mean dose of 662 micrograms.day-1 and sporadic booster courses of oral corticosteroids do not further increase bone mass loss with respect to that expected from natural bone mass loss.

This article has been cited by other articles:

				P. D. Scanlon, J. E. Connett, R. A. Wise, D. P. Tashkin, T. Madhok, M. Skeans, P. C. Carpenter, W. C. Bailey, A. S. Buist, M. Eichenhorn, et al. Loss of Bone Density with Inhaled Triamcinolone in Lung Health Study II Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1302 - 1309. [Abstract] [Full Text] [PDF]

				O. Gluck and G. Colice Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases Chest, May 1, 2004; 125(5): 1859 - 1876. [Abstract] [Full Text] [PDF]

				F. T. Leone, J. E. Fish, S. J. Szefler, and S. L. West Systematic Review of the Evidence Regarding Potential Complications of Inhaled Corticosteroid Use in Asthma: Collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology Chest, December 1, 2003; 124(6): 2329 - 2340. [Abstract] [Full Text] [PDF]

				P. K. Sharma, S. Malhotra, P. Pandhi, and N. Kumar Effect of Inhaled Steroids on Bone Mineral Density: A Meta-Analysis J. Clin. Pharmacol., February 1, 2003; 43(2): 193 - 197. [Abstract] [Full Text] [PDF]

				D. M. Biskobing COPD and Osteoporosis Chest, February 1, 2002; 121(2): 609 - 620. [Abstract] [Full Text] [PDF]

				H. Matsumoto, K. Ishihara, T. Hasegawa, B.-i. Umeda, A. Niimi, and M. Hino Effects of Inhaled Corticosteroid and Short Courses of Oral Corticosteroids on Bone Mineral Density in Asthmatic Patients : A 4-Year Longitudinal Study Chest, November 1, 2001; 120(5): 1468 - 1473. [Abstract] [Full Text] [PDF]

				E. Israel, T. R. Banerjee, G. M. Fitzmaurice, T. V. Kotlov, K. LaHive, and M. S. LeBoff Effects of Inhaled Glucocorticoids on Bone Density in Premenopausal Women N. Engl. J. Med., September 27, 2001; 345(13): 941 - 947. [Abstract] [Full Text] [PDF]

				The use of inhaled corticosteroids in adults with asthma DTB, January 1, 2000; 38(1): 5 - 8. [Abstract] [Full Text] [PDF]

				M. F. Goldstein, J. J. Fallon Jr, and R. Harning Chronic Glucocorticoid Therapy-Induced Osteoporosis in Patients With Obstructive Lung Disease* Chest, December 1, 1999; 116(6): 1733 - 1749. [Abstract] [Full Text] [PDF]

				B. J. Lipworth Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis Arch Intern Med, May 10, 1999; 159(9): 941 - 955. [Abstract] [Full Text] [PDF]